SpyGlass Pharma

Q2 FY2026 EarningsQ2 FY26 reported mixed results as a late-stage biopharmaceutical company: revenue remained at $0 as expected, while GAAP EPS of -$0.59 missed the consensus mean of -$0.53. Operating expenses surged to $21.97M, driven by Phase 3 clinical trial enrollment and $11.0M in G&A costs, including significant legal fees. Despite the earnings miss, the company maintains a robust liquidity position with $234.2M in cash and investments following its February 2026 IPO, providing a runway through 2028.